In contrast, lower expression of LAYN was observed in bladder urothelial cancer, breast cancer, colorectal cancer, kidney chromophobe, lung adenocarcinoma, prostate cancer, thyroid cancer, and endometrial cancer compared with adjacent normal tissues (Fig. 1A). This evidence concerns the gene LAYN and prostate carcinoma.